An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
Study Purpose
This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 18 Years - 80 Years |
Gender | All |
Inclusion and Exclusion Criteria are the same for both Stage 1 and Stage 2; however, participants enrolled in Stage 1 will not be permitted to enroll in Stage 2.
Inclusion Criteria:
1. At the time of signing the informed consent, the participant must be 18 to 80 years of age, inclusive. 2. A diagnosis of ileal, ileocolonic, or colonic CD with an onset of symptoms for a minimum of 3 months prior to Screening as determined by the investigator based on clinical history, exclusion of other etiologies including infectious causes, and characteristic endoscopic and/or histologic findings. 3. Moderately to severely active CD defined by a CDAI score of 220 to 450 AND; CDAI LSF score ≥ 5 OR CDAI AP score ≥ 2; AND SES-CD of at least 6. 4. Participant had an inadequate response or intolerance to intervention with conventional treatment [oral aminosalicylates, oral CS, azathioprine, methotrexate, or 6-mercaptopurine], or prior biological treatment, or demonstrated CS dependence for the treatment of CD. For participants who have previously used biological treatment, a participant may have failed up to 3 biologics that include up to 2 different mechanisms of action. 5. Participants taking 5-aminosalicylates, Oral prednisone (or equivalent), Budesonide, Immunomodulators, Oral antibiotics, Immunomodulators, Probiotics must be at a stable dose. 6. Participant must have the QFT-TB test performed and meet the following TB criteria. A TB worksheet must also be completed: 1. Participant has no known history of active TB. 2. Participant has no known history of latent TB without completion of an appropriate course of intervention. 3. Meets 1 of the following acceptable TB test results: i. Negative QFT-TB obtained from central laboratory during Screening, OR ii. For a positive QFT-TB test obtained during Screening from the central laboratory, active TB must be ruled out or treated and negative QFT-TB confirmed by central laboratory OR iii. Indeterminate QFT-TB test obtained during the Screening Period from the central laboratory with ongoing QFT-TB testing as outlined in Appendix G. Participants with an indeterminate QFT-TB test can continue with Screening if they have all of the following: 1. no symptoms/risk factors per TB worksheet provided by the sponsor. 2. no known recent exposure to a case of active TB. 3. no evidence of active TB on chest x-ray within 8 weeks prior to Screening or during Screening. 4. confirmed QFT-TB negative by central laboratory. 7 Female participants of childbearing potential must have a negative urine pregnancy test prior to administration of study intervention and must agree to use a highly effective method of birth control (confirmed by the investigator) from randomization throughout the study duration and for at least 18 weeks after last dose of study intervention. 8 Women not of childbearing potential are defined as women who are either permanently sterilized or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned date of randomization without an alternative medical cause. 9 Nonsterilized males who are sexually active with a female partner of childbearing potential must comply with the methods of contraception during treatment and until the end of relevant systemic exposure in the male participant, plus a further 18 weeks. 10 Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol. 11 Willingness and ability to attend all study visits, comply with the study procedures, read and write in order to complete questionnaires, and be able to complete the study period. 12 Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative. Complete inclusion criteria are in the study protocol.Exclusion Criteria:
1. Participant is unable or unwilling to have endoscopic procedures performed during the study. 2. History or current diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, colonic mucosal dysplasia, primary sclerosing cholangitis, or untreated bile acid malabsorption. 3. History of toxic megacolon within 3 months prior to Randomization. 4. Any intra-abdominal surgery, bowel resection, diversion, placement of ostomy or stoma within 3 months prior to Screening. Participants with a draining stoma, ostomy, or extensive colonic resection are excluded irrespective of the time from surgery. 5. Participant has an enterocutaneous or enterovesicular fistula. Participants with other active fistulas, including perianal fistulas, may be considered for enrollment if there is no anticipation for surgery and there is no evidence of active infection (eg, abscess). 6. Bowel perforation during the 6 months prior to Screening or evidence of obstruction within 3 months of Screening. 7. Complications of CD including short bowel syndrome, strictures/stenoses with obstruction or pre-stenotic dilation, or conditions where surgery may be anticipated within 6 months, or other conditions that may confound efficacy evaluations for the study. 8. Participant has any non-passable colonic stenosis/narrowing identified during the qualifying ileocolonoscopy (successful endoscope passage to the caecum with inability to enter the endoscope into the ileum is not covered under this exclusion criterion, and does not require exclusion). 9. Ongoing nutritional dependency for total parenteral nutrition or an elemental diet at Screening. 10. Participant has any of the following related to infections: • Evidence of a recent (within 6 months of Randomization) systemic fungal infection, requiring inpatient hospitalization, and/or antifungal treatment. • Any infection requiring hospitalization or treatment with IV anti-infectives (including antiviral treatment) within 4 weeks of Screening. • Cytomegalovirus or Epstein-Barr virus infection that has not resolved within 8 weeks prior to Screening • Clinically significant chronic infection (eg, osteomyelitis) that has not resolved within 8 weeks of Screening • Nonserious infection requiring oral anti-infectives within 2 weeks prior to randomization must be further discussed with the Study Physician/designee. • Participant has clinical evidence of or suspected to have an abscess during Screening. • Diagnosis of peritonitis or receiving treatment for peritonitis within 8 weeks prior to Screening • Participant has any underlying condition that predisposes participant to infections • Clinically significant active infection or signs/symptoms of infection that has the potential to worsen with immunosuppressive therapy • Signs or symptoms of ongoing infection due to intestinal pathogens. 11. Previous allogenic bone marrow transplant or history of organ or cell-based transplantation (eg, islet cell transplantation or autologous stem cell transplantation) with the exception of corneal transplant. 12. Chronic hepatitis B or C infection. 13. Known history of primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, includingHIV infection. 14. Prior history of or current diagnosis of a demyelinating disorder. 15. Participant has received the following treatment: • Adalimumab, certolizumab pegol, infliximab, or golimumab: within 8 weeks prior to Randomization • Vedolizumab or ustekinumab within 12 weeks prior to Randomization • Other prohibited medication, biologic or small molecule treatment within 5 half-lives prior to Randomization • Fecal microbiota transplantation: within 8 weeks prior to Screening ileocolonoscopy. 16. Except for ustekinumab, prior exposure to any biologic agent targeting IL-12 or IL-23. 17. Participants who received cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, tacrolimus (FK-506), or tofacitinib within 2 weeks prior to Screening Visit 1. 18. Known history of allergy to the study intervention formulation or any of its excipients or components of the delivery device, or to any other biologic therapy. 19. Participants received more than 1 dose of IV or intramuscular steroids within 2 weeks prior to Screening Visit 1. 20. Participant received topical (rectal) aminosalicylic acid (eg, mesalamine) or topical (rectal) steroids within 2 weeks prior to Randomization. 21. Participant received a Bacille Calmette-Guérin vaccination within 12 months of Randomization or any other live vaccine less than 4 weeks prior to Randomization or is planning to receive any such vaccine over the course of the study. 22. Participant has known or suspected history of chronic use of NSAIDs (defined as at least 3 times per week for more than 3 months; not applicable to daily aspirin use up to 325mg per day) and/or opiates, drug, or alcohol abuse. 23. History of cancer with the following exceptions: (a) A history of basal cell carcinoma and/or squamous cell carcinoma of the skin, with apparent successful curative therapy greater than 12 months prior to Screening (b) Carcinoma in situ of the cervix, with apparent successful curative therapy, greater than 12 months prior to Screening. 24. Clinically significant cardiovascular conditions including recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within 6 months of Screening. 25. Prolonged QTcF interval (QTc >450 msec or QTC >480 for participants with bundle branch block; determined on central ECG), or conditions leading to additional risk for QT prolongation (eg, congenital long-QT syndrome). 26. Clinically significant kidney disease. 27. Abnormal laboratory results at Screening. 28. Other concurrent medical conditions: Participant has known, preexisting, clinically significant endocrine, autoimmune, metabolic, neurologic, renal, gastrointestinal, hepatic, hematological, respiratory or any other system abnormalities that are not associated with CD and are uncontrolled with standard treatment. 29. Participant is currently enrolled in another investigational device or drug study, or is within 35 days or 5 half-lives, whichever is longer, since ending another investigational device or drug study, or receiving other investigational agent(s) 30. Transfusion of blood, plasma, or platelets within the 30 days prior to Screening. 31. Females who are pregnant, nursing, or planning a pregnancy during the study OR females who are of childbearing potential and do not agree to use a highly effective method of contraception consistently and correctly. 32. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 33. Previous randomization in the present study. . Complete exclusion criteria are in the study protocolTrial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT03759288 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2/Phase 3 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
AstraZeneca |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Kathy Bohannon |
Principal Investigator Affiliation | AstraZeneca |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
Overall Status | Recruiting |
Countries | Australia, Austria, Bulgaria, Canada, China, Czechia, France, Germany, Hungary, India, Israel, Italy, Korea, Republic of, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Spain, Taiwan, Ukraine, United Kingdom, United States |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Crohn's Disease, IBD |
Arms
Experimental: (Stage 1) Brazikumab high dose
Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Experimental: (Stage 1) Brazikumab low dose
Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Placebo Comparator: (Stage 1) Placebo
Intravenous placebo on Days 1, 29, and 57, followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
Experimental: (Stage 2) Brazikumab high dose
Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Experimental: (Stage 2) Brazikumab low dose
Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous on Day 85 and every 4 weeks through Week 48
Active Comparator: (Stage 2) Humira®
Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50
Interventions
Drug: - Brazikumab low dose
Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Drug: - Brazikumab high dose
Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Drug: - Humira®
Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
Drug: - Placebo
Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Not yet recruiting
Address
Research Site
Mobile, Alabama, 36606
Status
Withdrawn
Address
Research Site
Mesa, Arizona, 85206
Status
Not yet recruiting
Address
Research Site
Phoenix, Arizona, 85037
Status
Withdrawn
Address
Research Site
Scottsdale, Arizona, 85258
Status
Withdrawn
Address
Research Site
Scottsdale, Arizona, 85260
Status
Withdrawn
Address
Research Site
Tucson, Arizona, 85741
Status
Terminated
Address
Research Site
Little Rock, Arkansas, 72212
Status
Withdrawn
Address
Research Site
Beverly Hills, California, 90211
Status
Withdrawn
Address
Research Site
Camarillo, California, 93012
Status
Withdrawn
Address
Research Site
Chula Vista, California, 91911
Status
Withdrawn
Address
Research Site
Garden Grove, California, 92845
Status
Withdrawn
Address
Research Site
La Mesa, California, 91942
Status
Suspended
Address
Research Site
Lancaster, California, 93534
Status
Completed
Address
Research Site
Lincoln, California, 95648
Status
Withdrawn
Address
Research Site
Los Angeles, California, 90036
Status
Withdrawn
Address
Research Site
Los Angeles, California, 90073
Status
Not yet recruiting
Address
Research Site
Mission Hills, California, 91345
Status
Not yet recruiting
Address
Research Site
Newport Beach, California, 92660
Status
Withdrawn
Address
Research Site
Northridge, California, 91324
Status
Terminated
Address
Research Site
Poway, California, 92064
Status
Withdrawn
Address
Research Site
San Bernardino, California, 92408
Status
Terminated
Address
Research Site
San Diego, California, 92103
Status
Withdrawn
Address
Research Site
San Francisco, California, 94127
Status
Suspended
Address
Research Site
Colorado Springs, Colorado, 80907
Status
Withdrawn
Address
Research Site
Colorado Springs, Colorado, 80909
Status
Terminated
Address
Research Site
Boca Raton, Florida, 33487
Status
Active, not recruiting
Address
Research Site
Clearwater, Florida, 33756
Status
Withdrawn
Address
Research Site
Coral Gables, Florida, 33134
Status
Withdrawn
Address
Research Site
Doral, Florida, 33166
Status
Not yet recruiting
Address
Research Site
Gainesville, Florida, 32603
Status
Recruiting
Address
Research Site
Kissimmee, Florida, 34741
Status
Recruiting
Address
Research Site
Lakeland, Florida, 33813
Status
Recruiting
Address
Research Site
Miami, Florida, 33157
Status
Recruiting
Address
Research Site
Miami, Florida, 33165
Status
Withdrawn
Address
Research Site
Miami, Florida, 33165
Status
Terminated
Address
Research Site
Miami, Florida, 33189
Status
Not yet recruiting
Address
Research Site
Naples, Florida, 34102
Status
Recruiting
Address
Research Site
New Port Richey, Florida, 34653
Status
Withdrawn
Address
Research Site
Ocoee, Florida, 34761
Status
Recruiting
Address
Research Site
Pensacola, Florida, 32503
Status
Not yet recruiting
Address
Research Site
Saint Petersburg, Florida, 33709
Status
Terminated
Address
Research Site
Saint Petersburg, Florida, 33710
Status
Withdrawn
Address
Research Site
Tampa, Florida, 33606
Status
Active, not recruiting
Address
Research Site
Tampa, Florida, 33614
Status
Recruiting
Address
Research Site
Tampa, Florida, 33615
Status
Completed
Address
Research Site
Tampa, Florida, 33626
Status
Terminated
Address
Research Site
Atlanta, Georgia, 30328
Status
Not yet recruiting
Address
Research Site
Atlanta, Georgia, 30342
Status
Recruiting
Address
Research Site
Decatur, Georgia, 30033
Status
Withdrawn
Address
Research Site
Suwanee, Georgia, 30024
Status
Withdrawn
Address
Research Site
Arlington Heights, Illinois, 60005
Status
Withdrawn
Address
Research Site
Gurnee, Illinois, 60031
Status
Not yet recruiting
Address
Research Site
Oak Lawn, Illinois, 60453
Status
Not yet recruiting
Address
Research Site
Springfield, Illinois, 62702
Status
Terminated
Address
Research Site
Brownsburg, Indiana, 46112
Status
Withdrawn
Address
Research Site
New Albany, Indiana, 47150
Status
Withdrawn
Address
Research Site
Iowa City, Iowa, 52242
Status
Withdrawn
Address
Research Site
Shawnee Mission, Kansas, 66226
Status
Withdrawn
Address
Research Site
Topeka, Kansas, 66606
Status
Active, not recruiting
Address
Research Site
Marrero, Louisiana, 70072
Status
Withdrawn
Address
Research Site
New Orleans, Louisiana, 70121
Status
Recruiting
Address
Research Site
Baltimore, Maryland, 21202
Status
Withdrawn
Address
Research Site
Glen Burnie, Maryland, 21061
Status
Withdrawn
Address
Research Site
Rockville, Maryland, 20850
Status
Active, not recruiting
Address
Research Site
Chesterfield, Michigan, 48047
Status
Withdrawn
Address
Research Site
Farmington Hills, Michigan, 48334
Status
Not yet recruiting
Address
Research Site
Rochester, Minnesota, 55905
Status
Withdrawn
Address
Research Site
Biloxi, Mississippi, 39532
Status
Withdrawn
Address
Research Site
Saint Louis, Missouri, 63141
Status
Withdrawn
Address
Research Site
Lincoln, Nebraska, 68505
Status
Withdrawn
Address
Research Site
Papillion, Nebraska, 68046
Status
Withdrawn
Address
Research Site
Henderson, Nevada, 89052
Status
Withdrawn
Address
Research Site
Las Vegas, Nevada, 89106
Status
Terminated
Address
Research Site
Las Vegas, Nevada, 89123
Status
Completed
Address
Research Site
Albuquerque, New Mexico, 87108
Status
Withdrawn
Address
Research Site
Brooklyn, New York, 11218
Status
Withdrawn
Address
Research Site
Brooklyn, New York, 11235
Status
Withdrawn
Address
Research Site
New York, New York, 10016
Status
Not yet recruiting
Address
Research Site
Rochester, New York, 14642
Status
Withdrawn
Address
Research Site
Sunnyside, New York, 11104
Status
Recruiting
Address
Research Site
Greenville, North Carolina, 27834
Status
Terminated
Address
Research Site
Morehead City, North Carolina, 28557
Status
Completed
Address
Research Site
Beachwood, Ohio, 44122
Status
Withdrawn
Address
Research Site
Beavercreek, Ohio, 45431
Status
Withdrawn
Address
Research Site
Beavercreek, Ohio, 45440
Status
Withdrawn
Address
Research Site
Cincinnati, Ohio, 45219
Status
Withdrawn
Address
Research Site
Cincinnati, Ohio, 45236
Status
Withdrawn
Address
Research Site
Mentor, Ohio, 44060
Status
Withdrawn
Address
Research Site
Springfield, Ohio, 45503
Status
Recruiting
Address
Research Site
Oklahoma City, Oklahoma, 73102
Status
Withdrawn
Address
Research Site
Oklahoma City, Oklahoma, 73112
Status
Withdrawn
Address
Research Site
Oklahoma City, Oklahoma, 73118
Status
Withdrawn
Address
Research Site
Tulsa, Oklahoma, 74104
Status
Withdrawn
Address
Research Site
Tulsa, Oklahoma, 74145
Status
Active, not recruiting
Address
Research Site
Uniontown, Pennsylvania, 15401
Status
Withdrawn
Address
Research Site
Anderson, South Carolina, 29621
Status
Withdrawn
Address
Research Site
Greenville, South Carolina, 29615
Status
Withdrawn
Address
Research Site
Greer, South Carolina, 29650
Status
Withdrawn
Address
Research Site
Orangeburg, South Carolina, 29118
Status
Withdrawn
Address
Research Site
Johnson City, Tennessee, 37604
Status
Withdrawn
Address
Research Site
Amarillo, Texas, 79109
Status
Withdrawn
Address
Research Site
Austin, Texas, 78726
Status
Terminated
Address
Research Site
Carrollton, Texas, 75007
Status
Withdrawn
Address
Research Site
Dallas, Texas, 75234
Status
Terminated
Address
Research Site
Houston, Texas, 77017
Status
Not yet recruiting
Address
Research Site
Houston, Texas, 77030
Status
Withdrawn
Address
Research Site
Houston, Texas, 77030
Status
Recruiting
Address
Research Site
Houston, Texas, 77034
Status
Withdrawn
Address
Research Site
Houston, Texas, 77044
Status
Completed
Address
Research Site
Houston, Texas, 77058
Status
Terminated
Address
Research Site
McAllen, Texas, 78503
Status
Recruiting
Address
Research Site
McKinney, Texas, 75071
Status
Terminated
Address
Research Site
Pflugerville, Texas, 78660
Status
Recruiting
Address
Research Site
San Antonio, Texas, 78229
Status
Withdrawn
Address
Research Site
San Antonio, Texas, 78258
Status
Withdrawn
Address
Research Site
Spring, Texas, 77386
Status
Recruiting
Address
Research Site
Stafford, Texas, 77477
Status
Withdrawn
Address
Research Site
Bountiful, Utah, 84010
Status
Withdrawn
Address
Research Site
Ogden, Utah, 84405
Status
Not yet recruiting
Address
Research Site
Salt Lake City, Utah, 84132
Status
Terminated
Address
Research Site
North Chesterfield, Virginia, 23236
Status
Withdrawn
Address
Research Site
Seattle, Washington, 98195
Status
Not yet recruiting
Address
Research Site
Spokane, Washington, 99204
Status
Recruiting
Address
Research Site
Huntington, West Virginia, 25701
International Sites
Status
Withdrawn
Address
Research Site
Macquarie University, , 2109
Status
Withdrawn
Address
Research Site
Murdoch, , 6150
Status
Withdrawn
Address
Research Site
Innsbruck, , 6020
Status
Withdrawn
Address
Research Site
Ried, , 4910
Status
Not yet recruiting
Address
Research Site
Steyr, , 4400
Status
Not yet recruiting
Address
Research Site
Wels, , 4600
Status
Withdrawn
Address
Research Site
Plovdiv, , 4002
Status
Recruiting
Address
Research Site
New Westminster, British Columbia, V3L 3W4
Status
Withdrawn
Address
Research Site
Barrie, Ontario, L4M 7G1
Status
Recruiting
Address
Research Site
Hamilton, Ontario, L8S 4K1
Status
Withdrawn
Address
Research Site
Ottawa, Ontario, K1H 8L6
Status
Withdrawn
Address
Research Site
Toronto, Ontario, M3M 0B2
Status
Withdrawn
Address
Research Site
Toronto, Ontario, M5T 2S8
Status
Withdrawn
Address
Research Site
Vaughan, Ontario, L4L 4Y7
Status
Not yet recruiting
Address
Research Site
Chicoutimi, Quebec, G7H 5H6
Status
Withdrawn
Address
Research Site
Montreal, Quebec, H1M 1B1
Status
Withdrawn
Address
Research Site
Beijing, , 100032
Status
Withdrawn
Address
Research Site
Beijing, , 100034
Status
Withdrawn
Address
Research Site
Chengdu, , 610072
Status
Withdrawn
Address
Research Site
Chongqing, , 400010
Status
Withdrawn
Address
Research Site
Guangzhou, , 510100
Status
Withdrawn
Address
Research Site
Haidian District, , 100191
Status
Withdrawn
Address
Research Site
Nanjing, , 210029
Status
Withdrawn
Address
Research Site
Shanghai, , 200080
Status
Withdrawn
Address
Research Site
Shanghai, , CN-200120
Status
Withdrawn
Address
Research Site
Shanghai, ,
Status
Withdrawn
Address
Research Site
Shenzhen, , 518053
Status
Withdrawn
Address
Research Site
Shiyan, , 442005
Status
Withdrawn
Address
Research Site
Suzhou, , 215006
Status
Withdrawn
Address
Research Site
Wuhan, , 430060
Status
Withdrawn
Address
Research Site
Wuxi, , 214023
Status
Withdrawn
Address
Research Site
Brno, , 636 00
Status
Not yet recruiting
Address
Research Site
Ceske Budejovice, , 370 01
Status
Recruiting
Address
Research Site
Horovice, , 268 31
Status
Recruiting
Address
Research Site
Hradec Kralove, , 500 12
Status
Recruiting
Address
Research Site
Ostrava, , 702 00
Status
Withdrawn
Address
Research Site
Praha 2, , 120 00
Status
Suspended
Address
Research Site
Usti nad Labem, , 401 13
Status
Not yet recruiting
Address
Research Site
Amiens Cedex 1, , 80054
Status
Withdrawn
Address
Research Site
Bayonne, , 64100
Status
Not yet recruiting
Address
Research Site
Clermond Ferrand, , 63003
Status
Not yet recruiting
Address
Research Site
Clichy Cedex, , 92118
Status
Not yet recruiting
Address
Research Site
Montpellier Cedex 5, , 34295
Status
Not yet recruiting
Address
Research Site
Nice, , 06200
Status
Not yet recruiting
Address
Research Site
Paris, , 75018
Status
Not yet recruiting
Address
Research Site
Reims, , 51092
Status
Withdrawn
Address
Research Site
Saint Priest en Jarez, , 42270
Status
Recruiting
Address
Research Site
Augsburg, , 86156
Status
Withdrawn
Address
Research Site
Berlin, , 10117
Status
Recruiting
Address
Research Site
Berlin, , 10825
Status
Withdrawn
Address
Research Site
Berlin, , 12627
Status
Withdrawn
Address
Research Site
Bremen, , 28177
Status
Withdrawn
Address
Research Site
Dessau-Rosslau, , 6847
Status
Withdrawn
Address
Research Site
Dortmund, , 44137
Status
Withdrawn
Address
Research Site
Frankfurt, , 60313
Status
Recruiting
Address
Research Site
Hamburg, , 20251
Status
Withdrawn
Address
Research Site
Hamburg, , 22297
Status
Withdrawn
Address
Research Site
Hannover, , 30459
Status
Recruiting
Address
Research Site
Kiel, , 24105
Status
Withdrawn
Address
Research Site
Leipzig, , 04103
Status
Recruiting
Address
Research Site
Minden, , 32423
Status
Withdrawn
Address
Research Site
Munich, , 80331
Status
Withdrawn
Address
Research Site
Neuruppin, , 16816
Status
Recruiting
Address
Research Site
Remscheid, , 42859
Status
Recruiting
Address
Research Site
Ulm, , 89081
Status
Withdrawn
Address
Research Site
Weiden In Der Oberpfalz, , 92637
Status
Suspended
Address
Research Site
Budapest, , 1033
Status
Recruiting
Address
Research Site
Budapest, , 1082
Status
Not yet recruiting
Address
Research Site
Debrecen, , 4032
Status
Withdrawn
Address
Research Site
Gyöngyös, , 3200
Status
Recruiting
Address
Research Site
Kecskemét, , 6000
Status
Withdrawn
Address
Research Site
Szeged, , 6725
Status
Withdrawn
Address
Research Site
Szekszárd, , 7100
Status
Withdrawn
Address
Research Site
Ahemdabad, , 380054
Status
Not yet recruiting
Address
Research Site
Ahemdabad, , 380054
Status
Withdrawn
Address
Research Site
Ahmedabad, , 380006
Status
Withdrawn
Address
Research Site
Ahmedabad, , 380052
Status
Withdrawn
Address
Research Site
Assam, , 781006
Status
Withdrawn
Address
Research Site
Bangalore, , 560054
Status
Not yet recruiting
Address
Research Site
Bangalore, , 560054
Status
Withdrawn
Address
Research Site
Gandhinagar, , 382428
Status
Withdrawn
Address
Research Site
Hyderabad, , 500032
Status
Not yet recruiting
Address
Research Site
Hyderabad, , 500032
Status
Withdrawn
Address
Research Site
Hyderabad, , 500058
Status
Withdrawn
Address
Research Site
Jaipur, , 302001
Status
Not yet recruiting
Address
Research Site
Jaipur, , 302001
Status
Withdrawn
Address
Research Site
Jaipur, , 302004
Status
Withdrawn
Address
Research Site
Kolkatta, , 700026
Status
Withdrawn
Address
Research Site
Nagpur, , 440010
Status
Withdrawn
Address
Research Site
New Dehli, , 110029
Status
Withdrawn
Address
Research Site
New Delhi, , 110017
Status
Not yet recruiting
Address
Research Site
New Delhi, , 110017
Status
Withdrawn
Address
Research Site
New Delhi, , 110075
Status
Not yet recruiting
Address
Research Site
New Delhi, , 110075
Status
Withdrawn
Address
Research Site
Pune, , 411001
Status
Withdrawn
Address
Research Site
Rajkot, , 360004
Status
Not yet recruiting
Address
Research Site
Rajkot, , 360004
Status
Withdrawn
Address
Research Site
Secunderabad, , 500003
Status
Not yet recruiting
Address
Research Site
Secunderabad, , 500003
Status
Withdrawn
Address
Research Site
Surat, , 395002
Status
Not yet recruiting
Address
Research Site
Surat, , 395002
Status
Withdrawn
Address
Research Site
Wardha, , 442004
Status
Not yet recruiting
Address
Research Site
Wardha, , 442004
Status
Withdrawn
Address
Research Site
Haifa, , 31048
Status
Withdrawn
Address
Research Site
Haifa, , 3109601
Status
Recruiting
Address
Research Site
HaIFA, , 3109601
Status
Not yet recruiting
Address
Research Site
Jerusalem, , 9103102
Status
Withdrawn
Address
Research Site
Jerusalem, , 9362410
Status
Not yet recruiting
Address
Research Site
Kfar Saba, , 44218
Status
Not yet recruiting
Address
Research Site
Nazareth, , 16100
Status
Not yet recruiting
Address
Research Site
Petah Tikva, , 4941492
Status
Withdrawn
Address
Research Site
Ramat Gan, , 52621
Status
Withdrawn
Address
Research Site
Rehovot, , 76100
Status
Withdrawn
Address
Research Site
Tel Aviv, , 0
Status
Not yet recruiting
Address
Research Site
Belluno, , 32100
Status
Not yet recruiting
Address
Research Site
Bologna, , 40138
Status
Withdrawn
Address
Research Site
Caltanissetta, , 93100
Status
Withdrawn
Address
Research Site
Caserta, , 81100
Status
Not yet recruiting
Address
Research Site
Castellana Grotte, , 70013
Status
Withdrawn
Address
Research Site
Chieti, , 66100
Status
Not yet recruiting
Address
Research Site
Firenze, , 50134
Status
Withdrawn
Address
Research Site
Foggia, , 71100
Status
Recruiting
Address
Research Site
Garbagnate Milanese, , 20024
Status
Not yet recruiting
Address
Research Site
L Aquila, , 67100
Status
Not yet recruiting
Address
Research Site
Milano, , 20132
Status
Not yet recruiting
Address
Research Site
Milano, , 20154
Status
Withdrawn
Address
Research Site
Naples, , 80138
Status
Not yet recruiting
Address
Research Site
Napoli, , 80131
Status
Not yet recruiting
Address
Research Site
Padova, , 35128
Status
Not yet recruiting
Address
Research Site
Palermo, , 90127
Status
Recruiting
Address
Research Site
Pavia, , 27100
Status
Not yet recruiting
Address
Research Site
Roma, , 00157
Status
Withdrawn
Address
Research Site
Roma, , 00168
Status
Not yet recruiting
Address
Research Site
Rozzano, , 20089
Status
Withdrawn
Address
Research Site
Salerno, , 84131
Status
Recruiting
Address
Research Site
Busan, , 48108
Status
Recruiting
Address
Research Site
Daegu, , 42415
Status
Withdrawn
Address
Research Site
Seoul, , 03181
Status
Recruiting
Address
Research Site
Seoul, , 03722
Status
Recruiting
Address
Research Site
Seoul, , 06351
Status
Recruiting
Address
Research Site
Seoul, , 06591
Status
Recruiting
Address
Research Site
Seoul, , 156-755
Status
Recruiting
Address
Research Site
Wonju-si, , 26426
Status
Not yet recruiting
Address
Research Site
Białystok, , 15-276
Status
Recruiting
Address
Research Site
Bydgoszcz, , 85 168
Status
Recruiting
Address
Research Site
Bydgoszcz, , 85-079
Status
Recruiting
Address
Research Site
Chojnice, , 89-600
Status
Withdrawn
Address
Research Site
Częstochowa, , 42-202
Status
Withdrawn
Address
Research Site
Gdańsk, , 80-382
Status
Withdrawn
Address
Research Site
Katowice, , 40-752
Status
Recruiting
Address
Research Site
Kielce, , 25-355
Status
Withdrawn
Address
Research Site
Końskie, , 26-200
Status
Withdrawn
Address
Research Site
Krakow, , 31-501
Status
Recruiting
Address
Research Site
Kraków, , 31-513
Status
Withdrawn
Address
Research Site
Mysłowice, , 41-400
Status
Withdrawn
Address
Research Site
Nowa Sól, , 67-100
Status
Withdrawn
Address
Research Site
Nowy Targ, , 34-400
Status
Withdrawn
Address
Research Site
Poznan, , 60-529
Status
Withdrawn
Address
Research Site
Poznań, , 60-702
Status
Withdrawn
Address
Research Site
Pruszków, , 05-800
Status
Recruiting
Address
Research Site
Rzeszow, , 35-302
Status
Recruiting
Address
Research Site
Sopot, , 81-756
Status
Withdrawn
Address
Research Site
Szczecin, , 71-434
Status
Recruiting
Address
Research Site
Toruń, , 87-100
Status
Recruiting
Address
Research Site
Warszawa, , 00-635
Status
Not yet recruiting
Address
Research Site
Warszawa, , 02-507
Status
Recruiting
Address
Research Site
Warszawa, , 03-580
Status
Withdrawn
Address
Research Site
Wroclaw, , 51-162
Status
Withdrawn
Address
Research Site
Wroclaw, , 51-685
Status
Withdrawn
Address
Research Site
Wrocław, , 50-449
Status
Recruiting
Address
Research Site
Wrocław, , 52-210
Status
Withdrawn
Address
Research Site
Łódź, , 90-302
Status
Withdrawn
Address
Research Site
Łódź, , 93-338
Status
Recruiting
Address
Research Site
San Juan, , 00927
Status
Withdrawn
Address
Research Site
Bucharest, , 020125
Status
Suspended
Address
Research Site
Aramil, , 624002
Status
Suspended
Address
Research Site
Izhevsk, , 426035
Status
Suspended
Address
Research Site
Kazan, , 420008
Status
Suspended
Address
Research Site
Kemerovo, , 650000
Status
Suspended
Address
Research Site
Krasnodar, , 350072
Status
Suspended
Address
Research Site
Moscow, , 115419
Status
Suspended
Address
Research Site
Novosibirsk, , 630007
Status
Suspended
Address
Research Site
Perm, , 614000
Status
Withdrawn
Address
Research Site
Pyatigorsk, , 357500
Status
Suspended
Address
Research Site
Saint-Petersburg, , 195257
Status
Suspended
Address
Research Site
Saint-Petersburg, , 196143
Status
Suspended
Address
Research Site
Tomsk, , 634050
Status
Withdrawn
Address
Research Site
Velikiy Novgorod, , 173008
Status
Recruiting
Address
Research Site
Banska Bystrica, , 97401
Status
Withdrawn
Address
Research Site
Banska Bystrica, , 97405
Status
Not yet recruiting
Address
Research Site
Bratislava, , 81108
Status
Withdrawn
Address
Research Site
Bratislava, , 82007
Status
Withdrawn
Address
Research Site
Bratislava, , 83103
Status
Recruiting
Address
Research Site
Bratislava, , 851 07
Status
Recruiting
Address
Research Site
Kosice, , 04013
Status
Recruiting
Address
Research Site
Nitra, , 94901
Status
Withdrawn
Address
Research Site
Presov, , 08001
Status
Recruiting
Address
Research Site
Bloemfontein, , 9301
Status
Withdrawn
Address
Research Site
Bloemfontein, , 9301
Status
Withdrawn
Address
Research Site
Cape Town, , 1730
Status
Recruiting
Address
Research Site
Cape Town, , 7500
Status
Not yet recruiting
Address
Research Site
Cape Town, , 7708
Status
Withdrawn
Address
Research Site
Johannesburg, , 1827
Status
Recruiting
Address
Research Site
Johannesburg, , 1827
Status
Withdrawn
Address
Research Site
Johannesburg, , 2193
Status
Withdrawn
Address
Research Site
Plumstead, , 7800
Status
Recruiting
Address
Research Site
Plumstead, , 7800
Status
Withdrawn
Address
Research Site
Port Elizabeth, , 6001
Status
Recruiting
Address
Research Site
Pretoria, , 0002
Status
Recruiting
Address
Research Site
Madrid, , 28046
Status
Recruiting
Address
Research Site
Pamplona, , 31008
Status
Recruiting
Address
Research Site
Pontevedra, , 36071
Status
Withdrawn
Address
Research Site
Sevilla, , 41013
Status
Recruiting
Address
Research Site
Sevilla, , 41071
Status
Recruiting
Address
Research Site
Tomelloso, , 13700
Status
Recruiting
Address
Research Site
Valencia, , 46010
Status
Recruiting
Address
Research Site
Kaohsiung, , 80756
Status
Recruiting
Address
Research Site
Taichung, , 40201
Status
Recruiting
Address
Research Site
Taichung, , 40447
Status
Recruiting
Address
Research Site
Taipei City, , 114
Status
Recruiting
Address
Research Site
Taipei, , 100
Status
Recruiting
Address
Research Site
Taipei, , 11217
Status
Withdrawn
Address
Research Site
Dnipro, , 49000
Status
Withdrawn
Address
Research Site
Ivano-Frankivsk, ,
Status
Suspended
Address
Research Site
Kharkiv, , 61037
Status
Suspended
Address
Research Site
Kherson, , 73000
Status
Suspended
Address
Research Site
Kyiv, , 01023
Status
Withdrawn
Address
Research Site
Kyiv, , 01030
Status
Withdrawn
Address
Research Site
Kyiv, , 01033
Status
Withdrawn
Address
Research Site
Kyiv, , 02002
Status
Withdrawn
Address
Research Site
Kyiv, , 02132
Status
Withdrawn
Address
Research Site
Kyiv, , 03037
Status
Suspended
Address
Research Site
Kyiv, , 03680
Status
Suspended
Address
Research Site
Kyiv, , 04050
Status
Suspended
Address
Research Site
Kyiv, , 04078
Status
Withdrawn
Address
Research Site
Kyiv, , 1049
Status
Withdrawn
Address
Research Site
Kyiv, , 4107
Status
Suspended
Address
Research Site
Lviv, , 79059
Status
Withdrawn
Address
Research Site
Odesa, , 65114
Status
Withdrawn
Address
Research Site
Poltava, , 36011
Status
Suspended
Address
Research Site
Ternopil, , 46001
Status
Not yet recruiting
Address
Research Site
Uzhhorod, , 88018
Status
Withdrawn
Address
Research Site
Vinnytsia, , 21001
Status
Suspended
Address
Research Site
Vinnytsia, , 21009
Status
Not yet recruiting
Address
Research Site
Vinnytsya, , 21028
Status
Withdrawn
Address
Research Site
Zaporizhzhia, , 69600
Status
Withdrawn
Address
Research Site
Cardiff, , CF14 5GJ
Status
Withdrawn
Address
Research Site
Chorley, , PR7 7NA
Status
Not yet recruiting
Address
Research Site
Coventry, , CV2 2DX
Status
Withdrawn
Address
Research Site
Edgbaston, , B15 2SQ
Status
Withdrawn
Address
Research Site
Epsom, , KT18 7EG
Status
Withdrawn
Address
Research Site
Glasgow, , G20 OSP
Status
Withdrawn
Address
Research Site
Hexham, , NE46 1QJ
Status
Withdrawn
Address
Research Site
Liverpool, , L22 0LG
Status
Withdrawn
Address
Research Site
Manchester, , M15 6SX
Status
Not yet recruiting
Address
Research Site
Nottingham, , NG7 2UH
Status
Withdrawn
Address
Research Site
Reading, , RG2 0TG
Status
Withdrawn
Address
Research Site
Stockton, , TS19 8PE
Status
Not yet recruiting
Address
Research Site
West Bromwich, , B71 4HJ